At a press conference at SABCS 2014, Prof Hurvitz discusses the results of phase III Breast Cancer Trials of Oral Everolimus-1 (BOLERO-1) study.
This was a multicentre trial examining the effects of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2 advanced breast cancer.
Read the news story or watch the interview for more.